Sort
17,828 grants matching “crispr”
PROTECT - Harnessing PROTEin Degradation for Advanced Childhood Tumours
$506,676Stefan Pfister · German Cancer Research Center · OT2 · FY2024 · CA
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
$506,646Arlene H Sharpe · Harvard Medical School · U19 · FY2018 · AI
Mitochondrial nutrient transport and trophoblast differentiation
$506,633Sarah A Wernimont · University Of Minnesota · R01 · FY2024 · HD
Disabling the replication-competent HIV provirus in the reservoir by combined CRISPR-Cas action
$506,574Benjamin Berkhout · Academical Medical Center · R01 · FY2023 · AI
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
$506,551Christopher Austin Klebanoff · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Local and global epigenome regulation of senescence and aging
$506,404Shelley L Berger · University Of Pennsylvania · R01 · FY2025 · AG
Chromatin Organization Regulates Osteogenesis
$506,385Jane B Lian · University Of Vermont & St Agric College · R01 · FY2023 · DE
Chromatin Organization Regulates Osteogenesis
$506,385Jane B Lian · University Of Vermont & St Agric College · R01 · FY2020 · DE
Chromatin Organization Regulates Osteogenesis
$506,385Jane B Lian · University Of Vermont & St Agric College · R01 · FY2021 · DE
To study the EMT contributions in tumor metastasis and chemoresistance by using lineage tracing models
$506,382Dingcheng Gao · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA
Defining cellular receptors for the Bacillus cereus hemolysin BL toxin (HBL) and the development of anti-HBL therapies
$506,279Shihui Liu · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC
$506,274David Macpherson · Fred Hutchinson Cancer Center · U01 · FY2022 · CA
Employing CRISPR inactivation screening and in vivo models towards improving treatments for SCLC
$506,274David Macpherson · Fred Hutchinson Cancer Center · U01 · FY2023 · CA
Clinical Pharmacology, Drug Action and Pharmacogenetics
$506,206Radojka Savic · University Of California, San Francisco · T32 · FY2025 · GM
Selectively Targeting Oncogenic NRAS in Cancer
$506,088Kevin M Shannon · University Of California, San Francisco · R01 · FY2023 · CA
Selectively Targeting Oncogenic NRAS in Cancer
$506,084Kevin M Shannon · University Of California, San Francisco · R01 · FY2022 · CA
Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care
$505,996Changchun Liu · University Of Connecticut Sch Of Med/Dnt · U01 · FY2024 · CA
Traumatic axonal injury in the visual system: role of dual leucine zipper kinase
$505,956Vassilis E Koliatsos · Johns Hopkins University · R01 · FY2017 · EY
Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathy
$505,842Rama Natarajan · Beckman Research Institute/City Of Hope · R01 · FY2020 · DK
Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathy
$505,842Rama Natarajan · Beckman Research Institute/City Of Hope · R01 · FY2021 · DK
Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathy
$505,842Rama Natarajan · Beckman Research Institute/City Of Hope · R01 · FY2023 · DK
Transforming growth factor beta1, microRNAs, lncRNA and diabetic nephropathy
$505,842Rama Natarajan · Beckman Research Institute/City Of Hope · R01 · FY2022 · DK
Regulation of the Epstein-Barr Virus Lytic Switch
$505,743Benjamin Elison Gewurz · Brigham And Women'S Hospital · R01 · FY2025 · AI
Regulation of the Epstein-Barr Virus Lytic Switch
$505,743Benjamin Elison Gewurz · Brigham And Women'S Hospital · R01 · FY2024 · AI
Genetic and epigenetic mechanisms of FSHD pathogenesis
$505,724Kyoko Yokomori · University Of California-Irvine · R01 · FY2023 · AR